Schedule of Pharmaceutical Benefits - 1 May 2019 update

PBAC

1 May 2019 - The May 2019 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The May issue of the Schedule includes a number of new/revised listings:

  • Avelumab (Bavencio) - new medicine
  • Inotuzumab ozogamicin (Besponsa) - new medicine
  • Palbociclib (Ibrance) - new medicine
  • Sapropterin dihydrochloride (Kuvan) - new indication
  • Tofacitinib citrate (Xeljanz) - new indication

Read summary of PBS changes

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Listing , Australia